Adrenaclick™ auto-injector contains 1.1 mL epinephrine injection, USP (1 mg/mL), from which one dose of either 0.15 mg (0.15 mL) or 0.3 mg (0.3 mL) each is available for use by injection. The dose is administered by autoinjection after the patient prepares and fires Adrenaclick™ as directed. The remaining volume is not available for use and should be discarded.
Adrenaclick (epinephrine injection, USP) is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g. order Hymenoptera, which includes bees, wasps, hornets, yellow jackets and fire ants), and biting insects (e.g. triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g. radiocontrast media), and other allergens, as well as anaphylaxis to unknown substances (idiopathic anaphylaxis) or exercise-induced anaphylaxis. Adrenaclick is intended for immediate administration in patients with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight (See DOSAGE AND ADMINISTRATION section).
Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria, or angioedema. Adrenaclick is designed as emergency supportive therapy only and is not a replacement or substitute for immediate medical care.
Media Articles Related to Adrenaclick (Epinephrine)
Widespread incorrect use of epinephrine auto-injectors and asthma inhalers
Source: Allergy News From Medical News Today [2014.12.27]
Millions of Americans with severe allergies and asthma are prescribed medical devices to help relieve symptoms and sometimes, to treat potentially fatal allergic reactions.
Epinephrine first and fast for a severe allergic reaction
Source: Allergy News From Medical News Today [2014.12.04]
If you are one of the millions of Americans who experiences a severe allergic reaction to food, latex or an insect sting, you should know the first line of defense in combating the reaction is...
Experts Urge Quick Use of Epinephrine for Severe Allergic Reactions
Source: MedicineNet Anaphylaxis Specialty [2014.12.03]
Title: Experts Urge Quick Use of Epinephrine for Severe Allergic Reactions
Category: Health News
Created: 12/2/2014 12:00:00 AM
Last Editorial Review: 12/3/2014 12:00:00 AM
Published Studies Related to Adrenaclick (Epinephrine)
Effect of combined dexamethasone therapy with nebulized r-epinephrine or
salbutamol in infants with bronchiolitis: A randomized, double-blind, controlled
bronchodilators alone for the treatment of infants with bronchiolitis... CONCLUSIONS: This study adds to a body of evidence suggesting that
Restrictive deferred hydration combined with preemptive norepinephrine infusion
during radical cystectomy reduces postoperative complications and hospitalization
time: a randomized clinical trial. 
approach could result in reduced postoperative complication rate... CONCLUSION: A restrictive-deferred hydration combined with preemptive
Vasopressin compared with norepinephrine augments the decline of plasma cytokine
levels in septic shock. 
shock... CONCLUSIONS: Survivors of septic shock had greater decreases of cytokines,
Faster onset and more comfortable injection with alkalinized 2% lidocaine with
epinephrine 1:100,000. 
(IANBs)... CONCLUSIONS: Alkalinizing lidocaine with epinephrine toward physiologic pH
A comparison of the efficacy of 4% articaine with 1:100,000 epinephrine and 2%
lidocaine with 1:80,000 epinephrine in achieving pulpal anesthesia in maxillary
teeth with irreversible pulpitis. 
anesthesia in maxillary teeth with irreversible pulpitis... CONCLUSIONS: There was no significant difference in efficacy between 4% articaine
Clinical Trials Related to Adrenaclick (Epinephrine)
Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation [Recruiting]
Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics [Recruiting]
This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine
Inhalation Aerosol USP, an HFA-MDI (E004), using a stable isotope deuterium-labeled
epinephrine (epinephrine-d3) to differentiate the administered drug from the endogenous
epinephrine, in healthy male and female adult volunteers. The current study is designed for
a more thorough evaluation of the E004 Pharmacokinetics. Safety of E004 will also be
evaluated, under augmented dose conditions.
Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients [Recruiting]
This clinical study evaluates the 12-week efficacy and safety of Epinephrine HFA Inhalation
Aerosol HFA the proposed HFA formulation of metered dose inhaler (MDI) of Epinephrine, in
comparison to a Placebo-HFA control MDI and the currently marketed Primatene® Mist
(epinephrine CFC inhaler), in adolescent and adult subjects with asthma.
Test Predicting Adrenal Insufficiency in Volunteers Under Prednisone Treatment [Recruiting]
Suppression of the adrenal function is a common, potentially dangerous and unpredictable
consequence of short term high dose glucocorticoid treatment. Identification of patients at
risk would be of high clinical importance. The investigators hypothesized that the
dexamethasone-suppression-test predicts the subsequent development of corticosteroid induced
SPARTACUS: Subtyping Primary Aldosteronism: a Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan. [Recruiting]
Rationale: Primary hyperaldosteronism (PA) is the most frequent form of secondary
hypertension. In PA autonomous hypersecretion of aldosterone by one or both adrenal glands
causes hypertension that is often refractory to treatment. PA is usually caused by either a
unilateral aldosterone-producing (micro)adenoma (APA) or by bilateral adrenal hyperplasia
(BAH). Distinction between APA and BAH is critical since the former is treated with the aim
of cure by adrenalectomy, and the latter by mineralocorticoid receptor antagonists. This
distinction can be made by adrenal vein sampling (AVS), as recommended by The Endocrine
Society 2008 guideline or by CT-scanning, as is common practice in the Netherlands. AVS is
invasive, demands great skill, and is expensive, while CT-scanning is non-invasive, easy and
cheap, but might be less accurate. However, the advantage of AVS has never been demonstrated
in prospective randomized studies. Here we propose to perform a prospective, randomized,
multicenter study that compares effectiveness of AVS with effectiveness of CT-scanning for
the diagnosis of PA subtype.
Objective: To assess the quantity of antihypertensive medication needed in order to
normalize blood pressure in patients who have been managed for PA according to either AVS or
CT-scan. Secondary objectives: to assess potassium, costs of management and quality of life.
Study design: Prospective, randomized trial in a multi-centre setting. Two hundred patients
will be recruited within two years. Follow-up will be one year after (start of) treatment.
Study population: Adult patients with therapy-resistant hypertension, with or without
hypokalemia, caused by PA.
Intervention: Patients will be randomized to undergo either adrenal CT-scanning or AVS (with
pre-AVS adrenal CT-scanning for phlebography). The result of either of these tests will
determine the course of action: adrenalectomy for adenoma or MRAs for bilateral hyperplasia.
Main study parameters/endpoints: The quantity of antihypertensive drugs patients are using
to obtain target blood pressure, expressed in Daily Defined Dosages, is used as the main
study parameter. There is no criterion standard for accuracy of the diagnosis of PA-subtype,
but we assume that if treatment is based on a more accurate diagnosis, treatment is more
effective. The most important secondary endpoints are the costs of the diagnostic course and
long-term medical treatment and the quality of life as assessed by a validated
Page last updated: 2014-12-27